This Article Full Text (OnlineFirst PDF) All Versions of this Article: 0003319708321668v1 59/2_suppl/62S    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Google Scholar Articles by Efthimiadis, A. PubMed PubMed Citation Articles by Efthimiadis, A. Social Bookmarking                   What's this?

Rosuvastatin and Cardiovascular Disease: Did the Strongest Statin Hold the Initial Promises?

Aristotle's University of Thessaloniki

^* To whom correspondence should be addressed. E-mail: a_efthimiadis{at}hotmail.com.

	Abstract

Rosuvastatin is the latest and most potent statin currently on the market. It has the greatest efficacy compared with all other available statins on total cholesterol and low-density lipoprotein cholesterol (LDLC) reduction, and also provides a significant increase in high-density lipoprotein cholesterol (HDL-C) better than atorvastatin. Imaging studies showed a regression of atheroma in secondary prevention patients using an intravascular ultrasound technique and a hold of progression in primary prevention patients using carotid intima–media thickness as a surrogate marker. The JUPITER trial, a primary prevention large-scale, prospective study to examine the role of statin therapy in individuals with raised C-reactive protein but normal LDL-C levels, was recently terminated early due to a significant reduction of events in the rosuvastatin group. Rosuvastatin has held its initial promises as a very potent statin, with favourable effects on HDL, showing a regression or a halt of the atherosclerotic burden and reducing cardiovascular events in low-risk patients.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?